Combining iguratimod and tofacitinib for rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests combining two oral medications, iguratimod and tofacitinib (Xeljanz), to see if they work better together for rheumatoid arthritis that is not well controlled on current treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have a confirmed diagnosis of rheumatoid arthritis.
- You have moderately to highly active arthritis despite taking at least 3 months of a standard treatment (like methotrexate, a TNF blocker, or iguratimod or tofacitinib alone).
- You are not allergic to iguratimod or tofacitinib.
- You have not stopped iguratimod or tofacitinib before due to side effects.
- You do not have active infections, tuberculosis, hepatitis B/C, or serious heart problems, and you are not in another study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two newer oral medications—tofacitinib and upadacitinib—to see which works better and is safer when added to methotrexate for rheumatoid arthritis. Both medicines help calm the immune system's attack on joints.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't been controlled by multiple standard treatments. It aims to see if telitacicept can help reduce inflammation and improve symptoms.
This trial tests whether combining Telitacicept and Tofacitinib can help people with rheumatoid arthritis that hasn't improved with at least two other advanced treatments. The goal is to see if these drugs work better together for hard-to-treat cases.
This study tests a combination of two drugs (telitacicept and baricitinib) for people with stubborn rheumatoid arthritis that hasn't improved with other treatments. The goal is to see if this combination is safe and effective in reducing joint pain and inflammation.
This study tests whether combining two medicines—methotrexate and tofacitinib—works better for people with a specific type of rheumatoid arthritis. It may be a good fit if you have moderate to severe arthritis, have had a joint biopsy that shows a certain cell pattern, and haven't used similar treatments before.
This trial tests if combining two medications, infliximab and tofacitinib, works better than standard treatment for adults hospitalized with a severe flare of ulcerative colitis. If you have not been on these drugs before and meet certain health criteria, you may be able to join.
Hear when a new Rheumatoid Arthritis (RA trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.